Theratechnologies Shareholders Approve Arrangement with CB Biotechnology

Theratechnologies Inc. held a special meeting of shareholders to discuss the proposed plan of arrangement involving CB Biotechnology. The meeting was chaired by Frank Holler, Chair of the Board of Directors, and attended by Paul Lévesque, President and CEO, Philippe Dubuc, Senior VP and CFO, and Jocelyn Lafond, General Counsel and Corporate Secretary. The proposed arrangement was the sole agenda item for approval.

Theratechnologies Inc. (TSX: TH, NASDAQ: THTX), a commercial-stage biopharmaceutical company, has announced that its shareholders have overwhelmingly approved the previously announced plan of arrangement to be acquired by Future Pak affiliate CB Biotechnology, LLC. The approval was made at a special meeting of shareholders held on September 12, 2025, chaired by Frank Holler, Chair of the Board of Directors.

The arrangement resolution received strong support, with 97.44% approval from shareholders present or represented by proxy, and 97.43% approval from minority shareholders. The transaction is subject to customary closing conditions, including final approval from the Superior Court of Québec, with a hearing scheduled for September 16, 2025.

Theratechnologies focuses on the commercialization of innovative therapies that have the potential to redefine standards of care. Future Pak, the acquiring entity, is a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products. The acquisition aims to leverage Future Pak's robust infrastructure and partner network to deliver quality-first, patient-centric solutions.

The proposed arrangement is subject to several risks and uncertainties, including the possibility that the arrangement may not be completed on the same terms and conditions, or on the timing currently contemplated. Other risks include the Purchaser's ability to complete its anticipated debt financing, the failure by the Company to achieve any milestones relating to the CVRs, and the uncertainty surrounding the arrangement which could adversely affect the Company's retention of customers, business partners, and key employees.

For additional information, please contact Theratechnologies Inc. at investor inquiries: Philippe Dubuc, Senior Vice President and Chief Financial Officer, at pdubuc@theratech.com or 438-315-6608, and media inquiries: Julie Schneiderman, Senior Director, Communications & Corporate Affairs, at communications@theratech.com or 514-336-7800.